Results 71 to 80 of about 17,394 (186)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

Journal of Virus Eradication, 2015
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak   +16 more
doaj  

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

AIDS Research and Therapy, 2020
Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors.
Aurelio Orta-Resendiz, Roberto A. Rodriguez-Diaz, Luis A. Angulo-Medina, Mario Hernandez-Flores, Luis E. Soto-Ramirez   +4 more
doaj   +1 more source

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens [PDF]

, 2017
Objectives: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.
Acinapura R., Aho I., Aksak-Was B., Amele S., Antinori A., Bakowska E., Battegay M., Begovac J., Benfield T., Beniowski M., Blaxhult A., Bogner J., Bojesen A., Borodulina E., Bravo I., Bruun J., Burger D., Burke M., Caldeira L., Calmy A., Castagna A., Cavassini M., Chkhartishvili N., Clarke A., Clotet B., Clumeck N., Cozzi-Lepri A., D'Arminio Monforte A., De Wit S., Degen O., Delforge M., Domingo P., Duvivier C., Edwards S., Elbirt D., Elinav H., Esposito R., Falconer K., Fatkenheuer G., Fischer A. H., Flamholc L., Flisiak R., Florence E., Fontas E., Furrer H., Gabbuti A., Galli M., Gargalianos P., Gasiorowski J., Gatell J. M., Gazzard B., Gensing M., Gerstoft J., Gianotti N., Girard P. -M., Gottfredsson M., Gronborg Laut K., Grzeszczuk A., Gutierrez M., Hadziosmanovic V., Haouzi M., Hassoun G., Hemmer R., Horban A., Inglot M., Jablonowska E., Jevtovic D., Jilich D., Johnson A. M., Johnson M. A., Jou A., Karpov I., Katzenstein T., Khromova I., Kirk O., Knysz B., Kristensen D., Kronborg G., Kundro M., Kuznetsova A., Kuzovatova E., Kyselyova G., Laporte J. M., Larsen J. F., Lazzarin A., Leen C., Lichtner M., Losso M. H., Lourida P., Lundgren J. D., Machala L., Maciejewska K., Maeland A., Malolepsza E., Maltez F., Mansinho K., Mateo G., Matthews C., Matulionyte R., Mazeu I., Mazzotta F., Miro J. M., Mitsura V. M., Mocroft A., Moller N. F., Moreno S., Mozer-Lisewska I., Mularska E., Mulcahy F., Mussini C., Nielsen L. N., Oprea C., Orkin C., Ormaasen V., Ostergaard L., Paduto D., Panteleev A., Panteleev O., Parczewski M., Paredes R., Pedersen C., Peters L., Phillips A., Plazzi M., Podlekareva D., Pradier C., Puig J., Raben D., Radoi R., Reiss P., Ridolfo A., Ristola M., Rockstroh J., Rodriguez J. M., Rozentale B., Sambatakou H., Sambeat M. A., Scherrer A., Schmid P., Schmidt R., Schmied B., Schultze A., Scullard G., Sedlacek D., Shahar E., Shepherd L., Simons E., Sluzhynska M., Smiatacz T., Smidt J., Sonnerborg A., Staub T., Stefan C., Stellbrink H. J., Sthoeger Z. M., Szlavik J., Thalme A., Thiebaut R., Tomazic J., Trofimora T., Tural C., Turner D., Uzdaviniene V., Vandekerckhove L., Vassilenko A., Vdoushkina E., Viard J. -P., Vullo V., Weber J., Weber R., Wiese L., Wojcik K., Xylomenos G., Yakovlev A., Yust I., Zaccarelli M., Zangerle R., Zilmer K.   +177 more
core   +9 more sources

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

Retrovirology, 2010
Background In this study we successfully created a new approach to ART in SIVmac251 infected nonhuman primates. This drug regimen is entirely based on drugs affecting the pre-integration stages of replication and consists of only two nucleotidic ...
Greenhouse Jack, Yalley-Ogunro Jake, Chirullo Barbara, Iraci Nunzio, Collins Matt, Barreca Maria, Norelli Sandro, Lewis Mark G, Titti Fausto, Garaci Enrico, Savarino Andrea   +10 more
doaj   +1 more source

Improvement of neuropsychological performances and reduction of immune-activation markers after probiotic supplementation and change of life-style in an HIV positive male: targeting the microbiota to act on gut-brain axis [PDF]

, 2017
The gut-brain axis is widely in uenced by the intestinal microbiota and dysbiosis is consequently associated with a large dysregulation of its functions. Probiotic supplementation, reducing the harmful effects of dysbiosis, has shown positive effects not
Bianchi, Luigi, Cavallari, EUGENIO NELSON, Ceccarelli, Giancarlo, Corano Scheri, Giuseppe, D'Ettorre, Gabriella, Gabriella Di Girolamo,, Martiangela, Fratino, Vassalini, Paolo, Vullo, Vincenzo   +8 more
core  

Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy

Future Pharmacology
Pregnancy is associated with various physiological changes that can significantly impact the disposition of drugs. To further the insight into how pregnancy affects the pharmacokinetics of drugs at different stages, clinical studies can be simulated ...
Monika Berezowska, Paola Coppola, Venkatesh Pilla Reddy, Pradeep Sharma   +3 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants [PDF]

, 2008
Jessica Marinello, Christophe Marchand, Bryan T. Mott, Anjali Bain, Craig J. Thomas, Yves Pommier   +5 more
openalex   +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena, Gallo Anna L, D'Avolio Antonio, Tempestilli Massimo, Bellagamba Rita, Tommasi Chiara, Nicastri Emanuele, Pucillo Leopoldo P, Narciso Pasquale   +8 more
doaj   +1 more source

Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile [PDF]

, 2008
Francisco J. Blanco, Miguel Arredondo, Freddy Guevara, Carmen Garrido, Judit Morelló, Sonia Rodrı́guez-Nóvoa, Mònica Córdoba, Juan González‐Lahoz, Vincent Soriano   +8 more
openalex   +1 more source